off brand glp 1 FDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs Comparing Ozempic, Wegovy and Other

Lixisenatide and exenatide are much weaker GLP-1 drugs compared with semaglutide, tirzepatide and several others that are in clinical trials as shown below for weight loss

Both tirzepatide (since 2022) and semaglutide (since 2024) were placed on the shortage list, prompting a surge in sales of compounded alternatives

This degree of weight loss can shift patients from severe to mild OSA, or from mild OSA to below the diagnostic threshold entirely

Understanding the leptin induced suppression of GLP1 inputs to the hypothalamus during weight gain and/or in the obese state may provide an additional pathology of obesity and diabetes